GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00076459" target="_blank" >RIV/65269705:_____/22:00076459 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/22:00126321

Výsledek na webu

<a href="https://reader.elsevier.com/reader/sd/pii/S1043276022001229?token=7982FCC761ED2E64F458459E6FB9C0091AC18519E32A6D640F8F27DFAE6187F262A687F85864600C15E3367ACC54E092&originRegion=eu-west-1&originCreation=20221122134927" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S1043276022001229?token=7982FCC761ED2E64F458459E6FB9C0091AC18519E32A6D640F8F27DFAE6187F262A687F85864600C15E3367ACC54E092&originRegion=eu-west-1&originCreation=20221122134927</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.tem.2022.06.005" target="_blank" >10.1016/j.tem.2022.06.005</a>

Jazyk výsledku

angličtina

Název v původním jazyce

GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?

Popis výsledku v původním jazyce

Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impair-ment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position.

Název v anglickém jazyce

GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?

Popis výsledku anglicky

Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impair-ment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Trends in Endocrinology and Metabolism

ISSN

1043-2760

e-ISSN

1879-3061

Svazek periodika

33

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

628-638

Kód UT WoS článku

000877913500003

EID výsledku v databázi Scopus

2-s2.0-85134850918